In vitro anticancer activity of melanin-like nanoparticles for multimodal therapy of glioblastoma
Source abstract
Abstract
Abstract Glioblastoma (GBM) is one of the most aggressive and hard to treat cancers. Traditional anti-cancer treatment methods have low efficiency and the lifespan after diagnosis is only 12–18 months. Brain tumor cells overexpress many proteins that play an important role in tumor progression and can be used as therapeutic targets. One of the promising approaches in cancer treatment is down-regulation of an extracellular matrix glycoprotein – Tenascin-C (TN-C) through RNA interference therapy. However, the effective delivery of double stranded RNA with one strand complementary to TN-C mRNA sequence is difficult due to rapid degradation by nucleases and low intracellular uptake. Polydopamine (PDA), a biomimetic polymer characterized by high biocompatibility and simple modification ability, is commonly used in nanobiomedicine to create a drug/gene delivery vehicle. Furthermore, photothermal characteristics of this polymer enable its application in photothermal therapy (PTT), which is a great option for cancer treatment. Here we synthesize PDA nanoparticles (NPs) coated with polyamidoamine dendrimers generation 3.0 (DD3.0) for therapeutic anti-TN-C RNA and doxorubicin delivery. As prepared PDA@DD3.0 NPs are then used in combined drug delivery, gene silencing, and PTT of GBM. The obtained materials are analyzed in terms of physicochemical and photothermal properties as well as their cytotoxicity, using human GBM cells. The results demonstrate that the obtained nanocarriers are effective non-viral vehicle for combined therapeutic approach for killing glioma cells via anti-TN-C RNA delivery and combined chemo-PTT therapy (CT-PTT). The application of PDA@DD3.0 NPs contributed to the 3-fold reduction in the proliferation rate of GBM cells, a decrease in the level of TN-C expression (by 30%) and a reduction in the number of viable cells by up to 20%.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Extracellular vesicles in disease · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
NanoBioMedical Centre, Adam Mickiewicz University in Poznań, Wszechnicy Piastowskiej 3 , 61-614 Poznań , Poland
Institute of Molecular Biology and Biotechnology, Faculty of Biology, Adam Mickiewicz University in Poznań, Uniwersytetu Poznańskiego 6 , 61-614 Poznań , Poland
Department of Molecular Neurooncology, Institute of Bioorganic Chemistry of the Polish Academy of Sciences, Noskowskiego 12/14 , 61-704 Poznań , Poland
Faculty of Chemistry, Adam Mickiewicz University in Poznań, Uniwersytetu Poznańskiego 8 , 61-614 Poznań , Poland
Centre for Advanced Technologies, Adam Mickiewicz University in Poznań, Uniwersytetu Poznańskiego 10 , 61-614 Poznań , Poland
References (71)
Show source-provided references
1. Jovčevska I, Kočevar N, Komel R. Glioma and glioblastoma – how much do we (not) know? Mol Clin Oncol. 2013;1(6):935–41.10.3892/mco.2013.172 ↗
2. Bicker J, Alves G, Fortuna A, Falcão A. Blood-brain barrier models and their relevance for a successful development of CNS drug delivery systems: a review. Eur J Pharm Biopharm. 2014;87(3):409–32.10.1016/j.ejpb.2014.03.012 ↗
3. Mohammed S, Dinesan M, Ajayakumar T. Survival and quality of life analysis in glioblastoma multiforme with adjuvant chemoradiotherapy: a retrospective study. Rep Pract Oncol Radiother. 2022;27(6):1026–36.10.5603/RPOR.a2022.0113 ↗
4. Lee SY. Temozolomide resistance in glioblastoma multiforme. Genes Dis. 2016;3(3):198–210.10.1016/j.gendis.2016.04.007 ↗
5. Mitusova K, Peltek OO, Karpov TE, Muslimov AR, Zyuzin MV, Timin AS. Overcoming the blood–brain barrier for the therapy of malignant brain tumor: current status and prospects of drug delivery approaches. J Nanobiotechnol. 2022;20(1):412.10.1186/s12951-022-01610-7 ↗
6. Harder BG, Blomquist MR, Wang J, Kim AJ, Woodworth GF, Winkles JA, et al. Developments in Blood-Brain Barrier Penetrance and Drug Repurposing for Improved Treatment of Glioblastoma. Front Oncol. 2018;8:462.10.3389/fonc.2018.00462 ↗
7. Park SH, Kim MJ, Jung HH, Chang WS, Choi HS, Rachmilevitch I, et al. One-Year Outcome of Multiple Blood-Brain Barrier Disruptions With Temozolomide for the Treatment of Glioblastoma. Front Oncol. 2020;10:1663.10.3389/fonc.2020.01663 ↗
8. Seeta Rama Raju G, Benton L, Pavitra E, Yu JS. Multifunctional nanoparticles: recent progress in cancer therapeutics. Chem Commun (Camb). 2015;51(68):13248–59.10.1039/C5CC04643B ↗
9. Kim D, Shin K, Kwon SG, Hyeon T. Synthesis and biomedical applications of multifunctional nanoparticles. Adv Mater. 2018;30(49):e1802309.10.1002/adma.201802309 ↗
10. Parvanian S, Mostafavi SM, Aghashiri M. Multifunctional nanoparticle developments in cancer diagnosis and treatment. Sens Bio-Sens Res. 2017;13:81–7.10.1016/j.sbsr.2016.08.002 ↗
11. Mrówczyński R. Polydopamine-based multifunctional (nano)materials for cancer therapy. ACS Appl Mater Interfaces. 2018;10(9):7541–61.10.1021/acsami.7b08392 ↗
12. Bao G, Mitragotri S, Tong S. Multifunctional nanoparticles for drug delivery and molecular imaging. Annu Rev Biomed Eng. 2013;15:253–82.10.1146/annurev-bioeng-071812-152409 ↗
13. McCarthy JR, Weissleder R. Multifunctional magnetic nanoparticles for targeted imaging and therapy. Adv Drug Deliv Rev. 2008;60(11):1241–51.10.1016/j.addr.2008.03.014 ↗
14. Ribovski L, Hamelmann NM, Paulusse JMJ. Polymeric nanoparticles properties and brain delivery. Pharmaceutics. 2021;13(12):2045.10.3390/pharmaceutics13122045 ↗
15. Liu Z, Ji X, He D, Zhang R, Liu Q, Xin T. Nanoscale drug delivery systems in glioblastoma. Nanoscale Res Lett. 2022;17(1):27.10.1186/s11671-022-03668-6 ↗
16. Gregory JV, Kadiyala P, Doherty R, Cadena M, Habeel S, Ruoslahti E, et al. Systemic brain tumor delivery of synthetic protein nanoparticles for glioblastoma therapy. Nat Commun. 2020;11(1):5687.10.1038/s41467-020-19225-7 ↗
17. Marei HE. Multimodal targeting of glioma with functionalized nanoparticles. Cancer Cell Int. 2022;22(1):265.10.1186/s12935-022-02687-8 ↗
18. Xin Y, Huang M, Guo WW, Huang Q, Zhang LZ, Jiang G. Nano-based delivery of RNAi in cancer therapy. Mol Cancer. 2017;16(1):134.10.1186/s12943-017-0683-y ↗
19. Gao H, Cheng R, A. Santos H. Nanoparticle-mediated siRNA delivery systems for cancer therapy. View. 2021;2(3):20200111.10.1002/VIW.20200111 ↗
20. Swaminathan G, Shigna A, Kumar A, Byroju VV, Durgempudi VR, Dinesh Kumar L. RNA interference and nanotechnology: A promising alliance for next generation cancer therapeutics. Front Nanotechnol. 2021;3:694838.10.3389/fnano.2021.694838 ↗
21. Lozada-Delgado EL, Grafals-Ruiz N, Vivas-Mejía PE. RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials. Life Sci. 2017;188:26–36.10.1016/j.lfs.2017.08.027 ↗
22. Teng X-Q, Qu J, Li G-H, Zhuang H-H, Qu Q. Small interfering RNA for gliomas treatment: Overcoming hurdles in delivery. Front Cell Dev Biol. 2022;10:824299.10.3389/fcell.2022.824299 ↗
23. Harrison C. RNAi-based nanoparticles zap glioblastoma. Nat Rev Drug Discov. 2014;13(1):20.10.1038/nrd4214 ↗
24. Kozielski KL, Ruiz-Valls A, Tzeng SY, Guerrero-Cázares H, Rui Y, Li Y, et al. Cancer-selective nanoparticles for combinatorial siRNA delivery to primary human GBM in vitro and in vivo. Biomaterials. 2019;209:79–87.10.1016/j.biomaterials.2019.04.020 ↗
25. Grabowska M, Grześkowiak BF, Szutkowski K, Wawrzyniak D, Głodowicz P, Barciszewski J, et al. Nano-mediated delivery of double-stranded RNA for gene therapy of glioblastoma multiforme. PLOS One. 2019;14(3):e0213852.10.1371/journal.pone.0213852 ↗
26. Gulcher JR, Nies DE, Alexakos MJ, Ravikant NA, Sturgill ME, Marton LS, et al. Structure of the human hexabrachion (tenascin) gene. Proc Natl Acad Sci U S A. 1991;88(21):9438–42.10.1073/pnas.88.21.9438 ↗
27. Castaños-Velez E, Biberfeld P, Patarroyo M. Extracellular matrix proteins and integrin receptors in reactive and non-reactive lymph nodes. Immunology. 1995;86(2):270–8.
28. Orend G, Chiquet-Ehrismann R. Tenascin-C induced signaling in cancer. Cancer Lett. 2006;244(2):143–63.10.1016/j.canlet.2006.02.017 ↗
29. Fukushima T, Tezuka T, Shimomura T, Nakano S, Kataoka H. Silencing of insulin-like growth factor-binding protein-2 in human glioblastoma cells reduces both invasiveness and expression of progression-associated gene CD24. J Biol Chem. 2007;282(25):18634–44.10.1074/jbc.M609567200 ↗
30. Tchirkov A, Khalil T, Chautard E, Mokhtari K, Véronèse L, Irthum B, et al. Interleukin-6 gene amplification and shortened survival in glioblastoma patients. Br J Cancer. 2007;96(3):474–6.10.1038/sj.bjc.6603586 ↗
31. Nakada M, Nakada S, Demuth T, Tran NL, Hoelzinger DB, Berens ME. Molecular targets of glioma invasion. Cell Mol Life Sci. 2007;64(4):458–78.10.1007/s00018-007-6342-5 ↗
32. Pas J, Wyszko E, Rolle K, Rychlewski L, Nowak S, Zukiel R, et al. Analysis of structure and function of tenascin-C. Int J Biochem Cell Biol. 2006;38(9):1594–602.10.1016/j.biocel.2006.03.017 ↗
33. Sarkar S, Nuttall RK, Liu S, Edwards DR, Yong VW. Tenascin-C stimulates glioma cell invasion through matrix metalloproteinase-12. Cancer Res. 2006;66(24):11771–80.10.1158/0008-5472.CAN-05-0470 ↗
34. Zagzag D, Shiff B, Jallo GI, Greco MA, Blanco C, Cohen H, et al. Tenascin-C promotes microvascular cell migration and phosphorylation of focal adhesion kinase. Cancer Res. 2002;62(9):2660–8.
35. Wang Y, Sun Y, Geng N, Zheng M, Zou Y, Shi B. A biomimetic nanomedicine targets orthotopic glioblastoma by combinatorial co-delivery of temozolomide and a methylguanine-DNA methyltransferase inhibitor. Adv Ther. 2022;5(12):2200095.10.1002/adtp.202200095 ↗
36. Mujokoro B, Adabi M, Sadroddiny E, Adabi M, Khosravani M. Nano-structures mediated co-delivery of therapeutic agents for glioblastoma treatment: A review. Mater Sci Eng C Mater Biol Appl. 2016;69:1092–102.10.1016/j.msec.2016.07.080 ↗
37. Zhao M, van Straten D, Broekman MLD, Préat V, Schiffelers RM. Nanocarrier-based drug combination therapy for glioblastoma. Theranostics. 2020;10(3):1355–72.10.7150/thno.38147 ↗
38. Kaneshiro TL, Lu ZR. Targeted intracellular codelivery of chemotherapeutics and nucleic acid with a well-defined dendrimer-based nanoglobular carrier. Biomaterials. 2009;30(29):5660–6.10.1016/j.biomaterials.2009.06.026 ↗
39. Cheng D, Cao N, Chen J, Yu X, Shuai X. Multifunctional nanocarrier mediated co-delivery of doxorubicin and siRNA for synergistic enhancement of glioma apoptosis in rat. Biomaterials. 2012;33(4):1170–9.10.1016/j.biomaterials.2011.10.057 ↗
40. Jaque D, Martínez Maestro L, del Rosal B, Haro-Gonzalez P, Benayas A, Plaza JL, et al. Nanoparticles for photothermal therapies. Nanoscale. 2014;6(16):9494–530.10.1039/C4NR00708E ↗
41. Chen J, Ning C, Zhou Z, Yu P, Zhu Y, Tan G, et al. Nanomaterials as photothermal therapeutic agents. Prog Mater Sci. 2019;99:1–26.10.1016/j.pmatsci.2018.07.005 ↗
42. Kim M, Lee J-H, Nam J-M. Plasmonic photothermal nanoparticles for biomedical applications. Adv Sci (Weinh). 2019;6(17):1900471.10.1002/advs.201900471 ↗
43. Doughty ACV, Hoover AR, Layton E, Murray CK, Howard EW, Chen WR. Nanomaterial applications in photothermal therapy for cancer. Mater (Basel). 2019;12(5):799.10.3390/ma12050779 ↗
44. Mona LP, Songca SP, Ajibade PA. Synthesis and encapsulation of iron oxide nanorods for application in magnetic hyperthermia and photothermal therapy. Nanotechnol Rev. 2022;11(1):176–90.10.1515/ntrev-2022-0011 ↗
45. Haghighat Bayan MA, Dias YJ, Rinoldi C, Nakielski P, Rybak D, Truong YB, et al. Near-infrared light activated core-shell electrospun nanofibers decorated with photoactive plasmonic nanoparticles for on-demand smart drug delivery applications. J Polym Sci. 2023;61(7):521–33.10.1002/pol.20220747 ↗
46. Yan B-Y, Cao Z-K, Hui C, Sun T-C, Xu L, Ramakrishna S, et al. MXene@Hydrogel composite nanofibers with the photo-stimulus response and optical monitoring functions for on-demand drug release. J Colloid Interface Sci. 2023;648:963–71.10.1016/j.jcis.2023.06.024 ↗
47. Zheng P, Ding B, Li G. Polydopamine-incorporated nanoformulations for biomedical applications. Macromol Biosci. 2020;20(12):e2000228.10.1002/mabi.202000228 ↗
48. Jin A, Wang Y, Lin K, Jiang L. Nanoparticles modified by polydopamine: Working as "drug" carriers. Bioact Mater. 2020;5(3):522–41.10.1016/j.bioactmat.2020.04.003 ↗
49. Chen R, Zhu C, Fan Y, Feng W, Wang J, Shang E, et al. Polydopamine-based multifunctional platform for combined photothermal therapy, chemotherapy, and immunotherapy in malignant tumor treatment. ACS Appl Bio Mater. 2019;2(2):874–83.10.1021/acsabm.8b00718 ↗
50. Wang H, Williams GR, Xie X, Wu M, Wu J, Zhu L. Stealth polydopamine-based nanoparticles with red blood cell membrane for the chemo-photothermal therapy of cancer. ACS Appl Bio Mater. 2020;3(4):2350–9.10.1021/acsabm.0c00094 ↗
51. Liu G, Gao N, Zhou Y, Nie J, Cheng W, Luo M, et al. Polydopamine-based “four-in-one” versatile nanoplatforms for targeted dual chemo and photothermal synergistic cancer therapy. Pharmaceutics. 2019;11(10):507.10.3390/pharmaceutics11100507 ↗
52. Mrówczyński R, Grześkowiak BF. Biomimetic catechol-based nanomaterials for combined anticancer therapies. In: Jana S, Jana S, editors. Nanoengineering of biomaterials. Weinheim, Germany: Wiley-VCH GmbH; 2022. p. 145–80.10.1002/9783527832095.ch23 ↗
53. Lee H, Dellatore SM, Miller WM, Messersmith PB. Mussel-inspired surface chemistry for multifunctional coatings. Science (New York, NY). 2007;318(5849):426–30.10.1126/science.1147241 ↗
54. Ryu JH, Messersmith PB, Lee H. Polydopamine surface chemistry: A decade of discovery. ACS Appl Mater Interfaces. 2018;10(9):7523–40.10.1021/acsami.7b19865 ↗
55. Yue Y, Zhao X. Melanin-like nanomedicine in photothermal therapy applications. Int J Mol Sci. 2021;22(1):399.10.3390/ijms22010399 ↗
56. Tian L, Li X, Ji H, Yu Q, Yang M, Guo L, et al. Melanin-like nanoparticles: advances in surface modification and tumour photothermal therapy. J Nanobiotechnology. 2022;20(1):485.10.1186/s12951-022-01698-x ↗
57. Mrówczyński R, Nan A, Turcu R, Leistner J, Liebscher J, Polydopamine A. Versatile coating for surface-initiated ring-opening polymerization of lactide to polylactide. Macromol Chem Phys. 2015;216(2):211–7.10.1002/macp.201400380 ↗
58. Grześkowiak BF, Maziukiewicz D, Kozłowska A, Kertmen A, Coy E, Mrówczyński R. Polyamidoamine dendrimers decorated multifunctional polydopamine nanoparticles for targeted chemo- and photothermal therapy of liver cancer model. Int J Mol Sci. 2021;22(2):738.10.3390/ijms22020738 ↗
59. Jędrzak A, Grześkowiak BF, Coy E, Wojnarowicz J, Szutkowski K, Jurga S, et al. Dendrimer based theranostic nanostructures for combined chemo- and photothermal therapy of liver cancer cells in vitro. Colloids Surf B Biointerfaces. 2019;173:698–708.10.1016/j.colsurfb.2018.10.045 ↗
60. Maziukiewicz D, Grześkowiak BF, Coy E, Jurga S, Mrówczyński R. NDs@PDA@ICG conjugates for photothermal therapy of glioblastoma multiforme. Biomim (Basel). 2019;4(1):3.10.3390/biomimetics4010003 ↗
61. Maziukiewicz D, Mrówczyński R, Jurga S, Grześkowiak BF. Laser synthesized nanodiamonds with hyper-branched polyglycerol and polydopamine for combined imaging and photothermal treatment. Diam Relat Mater. 2022;128:109308.10.1016/j.diamond.2022.109308 ↗
62. Wu H, Wei M, Xu Y, Li Y, Zhai X, Su P, et al. PDA-based drug delivery nanosystems: A potential approach for glioma treatment. Int J Nanomed. 2022;17:3751–75.10.2147/IJN.S378217 ↗
63. Ho CC, Ding SJ. The pH-controlled nanoparticles size of polydopamine for anti-cancer drug delivery. J Mater Sci Mater Med. 2013;24(10):2381–90.10.1007/s10856-013-4994-2 ↗
64. Jędrzak A, Grześkowiak BF, Golba K, Coy E, Synoradzki K, Jurga S, et al. Magnetite nanoparticles and spheres for chemo- and photothermal therapy of hepatocellular carcinoma in vitro. Int J Nanomed. 2020;15:7923–36.10.2147/IJN.S257142 ↗
65. Bernsmann F, Frisch B, Ringwald C, Ball V. Protein adsorption on dopamine–melanin films: Role of electrostatic interactions inferred from ζ-potential measurements versus chemisorption. J Colloid Interface Sci. 2010;344(1):54–60.10.1016/j.jcis.2009.12.052 ↗
66. Tejido-Rastrilla R, Ferraris S, Goldmann WH, Grünewald A, Detsch R, Baldi G, et al. Studies on cell compatibility, antibacterial behavior, and zeta potential of Ag-containing polydopamine-coated bioactive glass-ceramic. Mater (Basel). 2019;12(3):500.10.3390/ma12030500 ↗
67. Fu J, Chen Z, Wang M, Liu S, Zhang J, Zhang J, et al. Adsorption of methylene blue by a high-efficiency adsorbent (polydopamine microspheres): Kinetics, isotherm, thermodynamics and mechanism analysis. J Chem Eng. 2015;259:53–61.10.1016/j.cej.2014.07.101 ↗
68. Su L, Yu Y, Zhao Y, Liang F, Zhang X. Strong antibacterial polydopamine coatings prepared by a shaking-assisted method. Sci Rep. 2016;6(1):24420.10.1038/srep24420 ↗
69. Ball V. Impedance spectroscopy and zeta potential titration of dopa-melanin films produced by oxidation of dopamine. Colloids Surf A: Physicochem Eng Asp. 2010;363(1):92–7.10.1016/j.colsurfa.2010.04.020 ↗
70. Matcovschii V, Lisii D, Gudumac V, Dorosenco S. Selective interstitial doxorubicin for recurrent glioblastoma. Clin Case Rep. 2019;7(12):2520–5.10.1002/ccr3.2546 ↗
71. Norouzi M, Yathindranath V, Thliveris JA, Kopec BM, Siahaan TJ, Miller DW. Doxorubicin-loaded iron oxide nanoparticles for glioblastoma therapy: a combinational approach for enhanced delivery of nanoparticles. Sci Rep. 2020;10(1):11292.10.1038/s41598-020-68017-y ↗